Compare AMN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMN | AKBA |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.3M | 729.1M |
| IPO Year | 2001 | 2014 |
| Metric | AMN | AKBA |
|---|---|---|
| Price | $16.38 | $1.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $21.70 | $6.25 |
| AVG Volume (30 Days) | 937.0K | ★ 4.0M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,716,913,000.00 | $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | N/A | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $14.87 | $1.45 |
| 52 Week High | $30.49 | $4.08 |
| Indicator | AMN | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 44.14 |
| Support Level | $15.66 | $1.45 |
| Resistance Level | $16.80 | $1.61 |
| Average True Range (ATR) | 0.53 | 0.08 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 36.51 | 90.20 |
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are; nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. A majority of its revenue is generated from the nurse and allied solutions segment which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.